He R, Qi P, Shu L, Ding Y, Zeng P, Wen G
J Exp Clin Cancer Res. 2025; 44(1):44.
PMID: 39915884
PMC: 11804008.
DOI: 10.1186/s13046-025-03313-x.
Topolewski P, Laski D, Lukasiewicz M, Domagala P, de Wilde R, Polak W
Cancers (Basel). 2024; 16(22).
PMID: 39594819
PMC: 11592521.
DOI: 10.3390/cancers16223862.
Sethasine S, Phaloprakarn C
Int Breastfeed J. 2024; 19(1):75.
PMID: 39533322
PMC: 11555891.
DOI: 10.1186/s13006-024-00684-3.
Abu Baker F, Zeina A, Taher R, Mouch S, Israel A
J Clin Med. 2024; 13(18).
PMID: 39337094
PMC: 11433373.
DOI: 10.3390/jcm13185608.
Li X, Hu Z, Shi Q, Qiu W, Liu Y, Liu Y
Oncogene. 2024; 43(42):3121-3136.
PMID: 39251845
DOI: 10.1038/s41388-024-03150-w.
GJB2 Promotes HCC Progression by Activating Glycolysis Through Cytoplasmic Translocation and Generating a Suppressive Tumor Microenvironment Based on Single Cell RNA Sequencing.
Liu H, Li X, Zhang C, Hao X, Cao Y, Wang Y
Adv Sci (Weinh). 2024; 11(39):e2402115.
PMID: 39162005
PMC: 11497106.
DOI: 10.1002/advs.202402115.
A Machine Learning Model to Predict Risk for Hepatocellular Carcinoma in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
Sarkar S, Alurwar A, Ly C, Piao C, Donde R, Wang C
Gastro Hep Adv. 2024; 3(4):498-505.
PMID: 39131709
PMC: 11307858.
DOI: 10.1016/j.gastha.2024.01.007.
Higher inflammatory response in hepatocellular carcinoma is associated with immune cell infiltration and a better outcome.
Oshi M, Chida K, Roy A, Mann G, An N, Yan L
Hepatol Int. 2024; 18(4):1299-1309.
PMID: 38898190
DOI: 10.1007/s12072-024-10678-2.
Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
Papadopoulos G, Giannousi E, Avdi A, Velliou R, Nikolakopoulou P, Chatzigeorgiou A
Front Cell Dev Biol. 2024; 12:1343806.
PMID: 38774646
PMC: 11106433.
DOI: 10.3389/fcell.2024.1343806.
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.
Chrysavgis L, Kazanas S, Bafa K, Rozani S, Koloutsou M, Cholongitas E
Int J Mol Sci. 2024; 25(7).
PMID: 38612640
PMC: 11012092.
DOI: 10.3390/ijms25073832.
Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review.
Ghazanfar H, Javed N, Qasim A, Sarin Zacharia G, Ghazanfar A, Jyala A
Cancers (Basel). 2024; 16(6).
PMID: 38539547
PMC: 10969013.
DOI: 10.3390/cancers16061214.
Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma.
Chen P, Li Y, Dai Y, Wang Z, Zhou Y, Wang Y
J Hepatocell Carcinoma. 2024; 11:581-594.
PMID: 38525158
PMC: 10960512.
DOI: 10.2147/JHC.S450460.
GDF11: An emerging therapeutic target for liver diseases and fibrosis.
Habibi P, Falamarzi K, Dehdari Ebrahimi N, Zarei M, Malekpour M, Azarpira N
J Cell Mol Med. 2024; 28(7):e18140.
PMID: 38494851
PMC: 10945076.
DOI: 10.1111/jcmm.18140.
Higher Inflammatory Response in Hepatocellular Carcinoma is Associated with Immune Cell Infiltration and a Better Outcome.
Oshi M, Chida K, Roy A, Mann G, An N, Yan L
Res Sq. 2024; .
PMID: 38260290
PMC: 10802714.
DOI: 10.21203/rs.3.rs-3768964/v1.
Unraveling the underlying pathogenic factors driving nonalcoholic steatohepatitis and hepatocellular carcinoma: an in-depth analysis of prognostically relevant gene signatures in hepatocellular carcinoma.
Ni Y, Lu M, Li M, Hu X, Li F, Wang Y
J Transl Med. 2024; 22(1):72.
PMID: 38238845
PMC: 10795264.
DOI: 10.1186/s12967-024-04885-6.
Improving HCC Prognostic Models after Liver Resection by AI-Extracted Tissue Fiber Framework Analytics.
Stulpinas R, Morkunas M, Rasmusson A, Drachneris J, Augulis R, Gulla A
Cancers (Basel). 2024; 16(1).
PMID: 38201532
PMC: 10778366.
DOI: 10.3390/cancers16010106.
Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).
Zhao Y, Zhou Y, Wang D, Huang Z, Xiao X, Zheng Q
Int J Mol Sci. 2023; 24(24).
PMID: 38139341
PMC: 10743953.
DOI: 10.3390/ijms242417514.
MiRNAs in Alcohol-Related Liver Diseases and Hepatocellular Carcinoma: A Step toward New Therapeutic Approaches?.
Jouve M, Carpentier R, Kraiem S, Legrand N, Sobolewski C
Cancers (Basel). 2023; 15(23).
PMID: 38067261
PMC: 10705678.
DOI: 10.3390/cancers15235557.
Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.
Vachliotis I, Valsamidis I, Polyzos S
Cancers (Basel). 2023; 15(21).
PMID: 37958479
PMC: 10650629.
DOI: 10.3390/cancers15215306.
Three-Dimensional Cell Cultures: The Bridge between In Vitro and In Vivo Models.
Urzi O, Gasparro R, Costanzo E, De Luca A, Giavaresi G, Fontana S
Int J Mol Sci. 2023; 24(15).
PMID: 37569426
PMC: 10419178.
DOI: 10.3390/ijms241512046.